Modality
Radioligand
MOA
Anti-Aβ
Target
Nectin-4
Pathway
Amyloid
EoEADHDObesity
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Dec 2030
Phase 1Current
NCT06175041
1,908 pts·Obesity
2020-02→2030-12·Terminated
NCT07864249
1,939 pts·ADHD
2025-05→2025-09·Terminated
3,847 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-077mo agoPh2 Data· ADHD
2030-12-274.7y awayPh2 Data· Obesity
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2025-09-07 · 7mo ago
ADHD
Ph2 Data
2030-12-27 · 4.7y away
Obesity
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06175041 | Phase 1/2 | Obesity | Terminated | 1908 | eGFR |
| NCT07864249 | Phase 1/2 | ADHD | Terminated | 1939 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| IDY-3466 | Ideaya Bio | NDA/BLA | Nectin-4 |